Ofirnoflast: a first-in-class NEK7-targeted inhibitor of the NLRP3 inflammasome.

已完结 10 由达姆发布于 2026/9/24 9:17:07

DOI:10.1080/1061186X.2025.2542856
作者：Alexis Mollard,?Devan Bursey,?William Burnett,?Taylor Avei,?Benjamin Bearss,?Ramesh Subbiah,?Viduth K Chaugule,?Naga Srinivas Tripuraneni,?Shipra Bijpuria,?Russ Teichert,?Chadwick Davis,?Margit Janat-
文献类型：期刊论文
补充材料：只需要正文

Taylor & Francis

Abstract：Ofirnoflast is a first-in-class, orally bioavailable NEK7 inhibitor currently undergoing Phase 2 clinical evaluation. It disrupts NLRP3 inflammasome assembly by targeting NEK7's scaffolding

应助信息

1天前

Book学术机器人

a656bae55f3611f1bd1b34735aa3bc31.pdf 已采纳

1天前

Book学术机器人

2026/9/24 9:17:07 Book学术AI机器人已找到文献并上传

2026/9/24 9:17:07 Book学术AI机器人收到请求，开始寻找文献

2026/9/24 9:17:07 已向机器人发送请求

1天前

达姆发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:Taylor & FrancisThe Role of AI Chatbot in Alleviating Anxiety Among Elderly People Living Alone in the Community: A Prospective Study.